SYRE Spyre Therapeutics Inc.
Price (delayed)
$28.75
Market cap
$1.46B
P/E Ratio
3.18
Dividend/share
N/A
EPS
$9.05
Enterprise value
$1.41B
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of
Highlights
The company's equity has surged by 146% QoQ
SYRE's EPS has soared by 119% QoQ and by 113% YoY
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
SYRE's revenue has shrunk by 100% QoQ and by 100% YoY
Key stats
What are the main financial stats of SYRE
Market
Valuations
Earnings
Shares outstanding
50.79M
Market cap
$1.46B
Enterprise value
$1.41B
Price to earnings (P/E)
3.18
Price to book (P/B)
3.09
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$185.95M
EBITDA
-$185.95M
Free cash flow
-$156.42M
Per share
Balance sheet
Liquidity
EPS
$9.05
Free cash flow per share
-$3.45
Book value per share
$9.29
Revenue per share
$0
TBVPS
$9.62
Total assets
$436.07M
Total liabilities
$61.68M
Debt
$0
Equity
$374.39M
Working capital
$413.61M
Debt to equity
0
Current ratio
19.7
Quick ratio
19.27
Net debt/EBITDA
0.24
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-50.5%
Return on equity
-159.9%
Return on invested capital
-95.8%
Return on capital employed
-44.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SYRE stock price
How has the Spyre Therapeutics stock price performed over time
Intraday
-2.08%
1 week
-1.13%
1 month
10.41%
1 year
106.83%
YTD
33.6%
QTD
22.29%
Financial performance
How have Spyre Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$156.17M
Net income
-$185.98M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
SYRE's revenue has shrunk by 100% QoQ and by 100% YoY
The net income has increased by 49% since the previous quarter and by 32% year-on-year
Spyre Therapeutics's operating income has increased by 42% QoQ and by 28% YoY
Growth
What is Spyre Therapeutics's growth rate over time
Valuation
What is Spyre Therapeutics stock price valuation
P/E
3.18
P/B
3.09
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SYRE's EPS has soared by 119% QoQ and by 113% YoY
The company's equity has surged by 146% QoQ
SYRE's P/B is 26% above its 5-year quarterly average of 2.5
SYRE's revenue has shrunk by 100% QoQ and by 100% YoY
Efficiency
How efficient is Spyre Therapeutics business performance
SYRE's return on invested capital has surged by 88% since the previous quarter
Spyre Therapeutics's ROA has soared by 79% YoY and by 56% from the previous quarter
Dividends
What is SYRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SYRE.
Financial health
How did Spyre Therapeutics financials performed over time
Spyre Therapeutics's total assets has surged by 79% YoY but it has decreased by 11% QoQ
The company's total liabilities has shrunk by 76% YoY and by 25% QoQ
Spyre Therapeutics's debt is 100% lower than its equity
The company's equity has surged by 146% QoQ
SYRE's debt to equity has surged by 100% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.